UK Accuses Drugmakers Of Anti-Competitive Agreements
Law360, London (February 28, 2019, 10:10 PM GMT) -- Actavis illegally made monthly payments to Waymade to not enter the market for a generic hormone-replacement treatment and then charged the country’s national health care provider excessive prices for the drug, the U.K.’s antitrust regulator said Thursday.
From 2011 to 2015, Waymade PLC obtained licenses but did not enter the market for hydrocortisone tablets and froze its own stock because it was receiving monthly payments from Actavis UK, formerly known as Auden Mckenzie, the Competition and Markets Authority said.
The price that the National Health Service had to pay for 30 hydrocortisone tablets nearly doubled during the period in question, forcing it...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!